New hope for Tough-to-Treat prostate cancer

NCT ID NCT03338790

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested three different drug combinations for men with advanced prostate cancer that had spread and was no longer responding to standard hormone therapy. It aimed to see if adding an immunotherapy drug (nivolumab) to other treatments was safe and could help shrink tumors or slow the cancer's growth. The trial involved 292 participants to find the most effective approach for controlling this difficult stage of the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Local Institution - 0001

Essen, 45122, Germany
Local Institution - 0002

Jena, 07747, Germany
Local Institution - 0004

Heidelberg, D-69120, Germany
Local Institution - 0006

Göttingen, 37075, Germany
Local Institution - 0007

Koblenz, 56068, Germany
Local Institution - 0009

Marietta, Georgia, 30060, United States
Local Institution - 0010

Rancho Mirage, California, 92270, United States
Local Institution - 0011

St Louis, Missouri, 63110, United States
Local Institution - 0012

Detroit, Michigan, 48201, United States
Local Institution - 0013

Heidelberg, Victoria, 3084, Australia
Local Institution - 0014

South Brisbane, Queensland, 4101, Australia
Local Institution - 0015

Camperdown, New South Wales, 2050, Australia
Local Institution - 0016

Elizabeth Vale, South Australia, 5112, Australia
Local Institution - 0017

Westmead, New South Wales, 2145, Australia
Local Institution - 0018

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Local Institution - 0019

Rio de Janeiro, Rio de Janeiro, 22793-080, Brazil
Local Institution - 0020

Belo Horizonte, Minas Gerais, 30110-022, Brazil
Local Institution - 0021

Porto Alegre, Rio Grande do Sul, 90035001, Brazil
Local Institution - 0022

Campinas, São Paulo, 13075-460, Brazil
Local Institution - 0024

Portland, Oregon, 97225, United States
Local Institution - 0025

Culiacán, Sinaloa, 80230, Mexico
Local Institution - 0026

Medellín, 0, Colombia
Local Institution - 0027

Montería, Departamento de Córdoba, 0, Colombia
Local Institution - 0029

Villejuif, 94800, France
Local Institution - 0030

Marseille, 13273, France
Local Institution - 0031

Lyon, 69008, France
Local Institution - 0032

Clermont-Ferrand, 63000, France
Local Institution - 0033

Besançon, 25030, France
Local Institution - 0034

Santiago, Santiago Metropolitan, 8420383, Chile
Local Institution - 0035

Omaha, Nebraska, 68130, United States
Local Institution - 0036

Daphne, Alabama, 36526, United States
Local Institution - 0037

Miami, Florida, 33176, United States
Local Institution - 0038

Albany, New York, 12208, United States
Local Institution - 0039

Fairfax, Virginia, 22031, United States
Local Institution - 0040

Rockville, Maryland, 20850, United States
Local Institution - 0041

Durham, North Carolina, 27710, United States
Local Institution - 0042

Capital Federal, Buenos Aires, 1426, Argentina
Local Institution - 0043

CABA, 1199, Argentina
Local Institution - 0044

Buenos Aires, Distrito Federal, C1280, Argentina
Local Institution - 0045

Madrid, 28041, Spain
Local Institution - 0046

Pamplona, 31008, Spain
Local Institution - 0047

Seville, 41013, Spain
Local Institution - 0048

Guadalajara, Jalisco, 44280, Mexico
Local Institution - 0049

New Haven, Connecticut, 06520, United States
Local Institution - 0050

Clayton, Victoria, 0, Australia
Local Institution - 0051

Viña del Mar, Región de Valparaíso, 2540364, Chile
Local Institution - 0052

CABA, Buenos Aires, 1426, Argentina
Local Institution - 0053

Allentown, Pennsylvania, 18103, United States
Local Institution - 0054

León, Guanajuato, 37000, Mexico
Local Institution - 0055

Hamilton, Ontario, L8V 5C2, Canada
Local Institution - 0056

Québec, Quebec, G1J 1Z4, Canada
Local Institution - 0059

Moncton, New Brunswick, E1C 6Z8, Canada
Local Institution - 0061

Guadalajara, Jalisco, 44130, Mexico
Local Institution - 0062

Villa Siburu, Córdoba Province, 5003, Argentina
Local Institution - 0064

München, 81675, Germany
Local Institution - 0065

Louisville, Kentucky, 40207, United States
Local Institution - 0066

Montreal, Quebec, H2X 0C1, Canada
Local Institution - 0067

Kelowna, British Columbia, V1Y 5L3, Canada
Local Institution - 0068

New York, New York, 10032, United States
Local Institution - 0069

Jackson, Mississippi, 39202, United States
Local Institution - 0071

São Paulo, São Paulo, 05652-900, Brazil
Local Institution - 0073

São Paulo, São Paulo, 01308-050, Brazil
Local Institution - 0074

Belo Horizonte, Minas Gerais, 30130-090, Brazil
Local Institution - 0075

Curitiba, Paraná, 81480-580, Brazil
Tulane University

New Orleans, Louisiana, 70112, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER